UNSPSC 51112500: Alkylating agent nitrogen mustard compounds

This classification denotes cytotoxic chemotherapy agents, many based on C5H11Cl2N or mustine, and which chemically closely resemble - or are often identical to - WWI blister agents, substances called nitrogen mustards, that constitute reactive chemicals that introduce into biologically active molecules alkyl radicals and thereby disrupt functioning of the same, substances called alkyl-ating agents, thus the term ALKYLATING AGENT NITROGEN MUSTARD COMPOUNDS.

UNSPSC 51112500 Alkylating agent nitrogen mustard compounds is a Class code that nominally addresses chemotherapy agents used in oncology and hematology treatment. However, the most recent state and local procurement activity tagged to this code shows little direct relevance to the code's pharmaceutical scope. The Texas Health and Human Services Commission (HHS) posted a Request for Information (RFI) in April 2026 seeking vendor capabilities for a Therapeutic Pharmacy Initiative (TPI) Direct-to-Manufacturer Prescriptions program — a market-intelligence exercise focused on pharmacy benefit program structure, direct contracting models with pharmaceutical manufacturers, and prescription fulfillment efficiency rather than procurement of alkylating agents themselves. The RFI solicits information about vendors' experience with self-insured employer and government health plan contracting, negotiated net pricing approaches outside traditional pharmacy benefit manager and group purchasing organization channels, and outcomes-based agreement implementation.

The code shows minimal recent activity in state and local procurement tied to its actual commodity scope. The Texas HHS Commission RFI, posted April 3, 2026 with the same-day response deadline, appears to be a preliminary information-gathering mechanism rather than a formal solicitation for alkylating agent compounds. The RFI documentation specifies no award value, budget range, set-aside designation, or formal competitive criteria — it functions as exploratory procurement strategy development ahead of potential future formal RFPs. The geographic footprint and issuing-body mix remain unclear from this single opportunity, and the mismatch between the code's intended scope and the actual work being solicited suggests this code may not be actively pursued by state and local buyers for its nominal pharmaceutical application at present.